

# **Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/BAE5620BBA51EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: BAE5620BBA51EN

## **Abstracts**

The 7 major breast cancer markets are expected to exhibit a CAGR of 5.58% during 2024-2034.

The breast cancer market has been comprehensively analyzed in IMARC's new report titled "Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Breast cancer is a type of oncological disease that develops when unhealthy cells in the breast grow and divide uncontrollably, forming a tumor. This tumor can invade surrounding tissues and potentially spread to other parts of the body through the lymphatic system or bloodstream. The ailment may not cause noticeable symptoms in the early stages; however, as cancer progresses, indications may include a lump or thickening in the breast or underarm, nipple discharge, skin ulceration, changes in breast size or shape, persistent pain, tenderness, etc. The diagnosis of this illness typically involves a combination of the patient's medical history, physical examination, and clinical findings. Various imaging studies, such as mammography, ultrasound, magnetic resonance imaging (MRI), etc., may be used to evaluate the affected region. These investigations help to visualize the breast tissue and can detect any abnormalities or suspicious areas. Furthermore, the healthcare provider may recommend a biopsy, along with its pathological analysis, to determine if cancerous cells are present and, if so, to classify the type of tumor.

The increasing cases of mutations in genes that are involved in repairing damaged DNA and maintaining the stability of the cell's genetic material are primarily driving the breast cancer market. In addition to this, the rising prevalence of various associated risk factors, such as hormonal imbalance, advancing age, early menstruation or late menopause, obesity, exposure to certain radiation, etc., is also creating a positive

outlook for the market. Moreover, the widespread adoption of breast-conserving surgery, which provides substantial psychological and emotional benefits for women who are willing to maintain the natural appearance of their breasts, is further bolstering the market growth. Apart from this, the inflating application of immunotherapy, since it works by enhancing the body's defense system to recognize and attack cancerous cells while sparing healthy tissues, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intensity-modulated radiation therapy, owing to its numerous advantages, like precise dose delivery, reduced side effects, and improved treatment flexibility, is expected to drive the breast cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the breast cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the breast cancer market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the breast cancer market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the breast cancer market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current breast cancer marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

Market Insights

How has the breast cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the breast cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the breast cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of breast cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of breast cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of breast cancer by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with breast cancer across the seven major markets?

What is the size of the breast cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of breast cancer?

What will be the growth rate of patients across the seven major markets?

### Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for breast cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the breast cancer market?

What are the key regulatory events related to the breast cancer market?

What is the structure of clinical trial landscape by status related to the breast cancer

market?

What is the structure of clinical trial landscape by phase related to the breast cancer market?

What is the structure of clinical trial landscape by route of administration related to the breast cancer market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BREAST CANCER - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 BREAST CANCER - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 BREAST CANCER - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 BREAST CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 BREAST CANCER - UNMET NEEDS**

## **10 BREAST CANCER - KEY ENDPOINTS OF TREATMENT**

## **11 BREAST CANCER - MARKETED PRODUCTS**

- 11.1 List of Breast Cancer Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Arimidex (Anastrozole) - AstraZeneca Pharmaceuticals
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Aromasin (Exemestane) - Pfizer
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Evista (Raloxifene Hydrochloride) - Eli Lilly and Company
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Femara (Letrozole) - Novartis Pharmaceuticals
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Herceptin (Trastuzumab) - Genentech, Inc
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 BREAST CANCER - PIPELINE DRUGS**

- 12.1 List of Breast Cancer Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 SV-BR-1-GM - BriaCell Therapeutics Corporation
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 Dato-DXd - Daiichi Sankyo, Inc.
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 Idiratuzumab vedotin - Merck/Seagen
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Pembrolizumab/Vibostolimab - Merck Sharp & Dohme LLC
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 LOXO-783 - Loxo Oncology
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. BREAST CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. BREAST CANCER – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 BREAST CANCER - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Breast Cancer - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Breast Cancer - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Breast Cancer - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Breast Cancer - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Breast Cancer - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Breast Cancer - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Breast Cancer - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Breast Cancer - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Breast Cancer - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Breast Cancer - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Breast Cancer - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Breast Cancer - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Breast Cancer - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Breast Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Breast Cancer - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Breast Cancer - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Breast Cancer - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Breast Cancer - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Breast Cancer - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Breast Cancer - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Breast Cancer - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Breast Cancer - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Breast Cancer - Access and Reimbursement Overview

## **16 BREAST CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 BREAST CANCER MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 BREAST CANCER MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BAE5620BBA51EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BAE5620BBA51EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

